Current Review of Delta Variant of SARS-CoV-2



Abstract Views
1281

Downloads
477

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Oct 24, 2021
Published Nov 23, 2021
10.24018/ejmed.2021.3.6.1120

Abstract viewed = 1281 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Mutations are causing SARS-CoV-2 to alter its genetic structure to improve its potential to elude the immune system, making vaccine buildout against the virus more difficult. Multiple SARS-CoV-2 variants have been found up to this point; based on their impact on public health some are considered variants of concern (VOCs) and some are considered variants of interests. VOCs are linked to superior transmissibility, a decline in neutralization by natural or vaccine induced antibodies, evading capability of detection, and a reduction in the efficacy of vaccines or therapeutics. In this article, a SARS-CoV-2 subtype, known as Delta, has been revised to provide the current state of the art and an appropriate foundation for future research works. The evolution, pathogenesis, current trends of transmission, associated symptoms, suggested prevention and treatments, and vaccine efficacy of Delta variant are reviewed and discussed.

Keywords: COVID-19, delta, variants, treatment, vaccine efficacy

Downloads

Download data is not yet available.

References

  1. Coronavirus Cases [Internet]. Worldometers.info. [cited 2021 Oct 20]. Available from: https://www.worldometers.info/coronavirus/.
     Google Scholar
  2. Tracking SARS-CoV-2 variants [Internet]. Who.int. [cited 2021 Oct 20]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.
     Google Scholar
  3. CDC. Delta variant: What we know about the science [Internet]. Cdc.gov. 2021 [cited 2021 Oct 21]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html?s_cid=11512:cdc%20delta%20variant:sem.ga:p:RG:GM:gen:PTN:FY21.
     Google Scholar
  4. Cosdon N. Delta variant causes unprecedented COVID-19 disease in children [Internet]. Contagion Live. 2021 [cited 2021 Oct 21]. Available from: https://www.contagionlive.com/view/delta-variant-icauses-unprecedented-covid-19-disease-in-children.
     Google Scholar
  5. GISAID - hCov19 Variants [Internet]. Gisaid.org. [cited 2021 Oct 21]. Available from: https://www.gisaid.org/hcov19-variants/.
     Google Scholar
  6. IANS. Delta coronavirus variant has spread to 185 countries, says WHO [Internet]. Business-standard.com. 2021 [cited 2021 Oct 24]. Available from: https://www.business-standard.com/article/current-affairs/delta-coronavirus-variant-has-spread-to-185-countries-says-who-121092200721_1.html.
     Google Scholar
  7. CDC. COVID Data Tracker [Internet]. Cdc.gov. 2020 [cited 2021 Oct 24]. Available from: https://covid.cdc.gov/covid-data-tracker/.
     Google Scholar
  8. CDC. What is Genomic Surveillance? [Internet]. Cdc.gov. 2021 [cited 2021 Oct 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-surveillance.html.
     Google Scholar
  9. Wikipedia contributors. SARS-CoV-2 Delta variant [Internet]. Wikipedia, The Free Encyclopedia. 2021 [cited 2021 Oct 24]. Available from: https://en.wikipedia.org/w/index.php?title=SARS-CoV-2_Delta_variant&oldid=1055338617.
     Google Scholar
  10. CDC. SARS-CoV-2 Variant Classifications and Definitions [Internet]. Cdc.gov. 2021 [cited 2021 Oct 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.
     Google Scholar
  11. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583(7816): 459–468.
    DOI  |   Google Scholar
  12. Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms. 2021; 9(7).
    DOI  |   Google Scholar
  13. Becerra A, Muñoz-Velasco I, Aguilar-Cámara A, Cottom-Salas W, Cruz-González A, Vázquez-Salazar A, et al. Two short Low complexity regions (LCRs) are hallmark sequences of the Delta SARS-CoV- 2 variant spike protein. Research Square. 2021.
    DOI  |   Google Scholar
  14. Chowdhury S, Bappy MH. On the delta plus variant of SARS-CoV-2. ResearchGate. [Preprint] 2021. http://dx.doi.org/10.13140/RG.2.2.27004.46724/1.
     Google Scholar
  15. Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, et al. Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021; 124(102715): 102715.
    DOI  |   Google Scholar
  16. CDC. Symptoms of COVID-19 [Internet]. Cdc.gov. 2021 [cited 2021 Oct 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
     Google Scholar
  17. ZOE COVID Study - Help slow the spread of COVID-19 [Internet]. Joinzoe.com. [cited 2021 Oct 24]. Available from: https://covid.joinzoe.com/us-2.
     Google Scholar
  18. FDA. Fact sheet for health care providers emergency use authorization (eua) of regen-cov [Internet]. Fda.gov. [cited 2021 Oct 24]. Available from: https://www.fda.gov/media/145611/download.
     Google Scholar
  19. FDA. Fact sheet for health care providers emergency use authorization (Eua) of bamlanivimab and etesevimab [Internet]. Fda.gov. [cited 2021 Oct 24]. Available from: https://www.fda.gov/media/145802/download.
     Google Scholar
  20. FDA. Fact sheet for healthcare providers emergency use authorization (Eua) of sotrovimab [Internet]. Fda.gov. [cited 2021 Oct 24]. Available from: https://www.fda.gov/media/149534/download.
     Google Scholar
  21. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871): 276–80.
    DOI  |   Google Scholar
  22. Hinton DM. Convalescent Plasma EUA Letter of Authorization 06032021 [Internet]. Fda.gov. [cited 2021 Oct 24]. Available from: https://www.fda.gov/media/141477/download.
     Google Scholar
  23. UpToDate [Internet]. Uptodate.com. [cited 2021 Oct 24]. Available from: https://www.uptodate.com/contents/covid-19-management-in-hospitalized-adults?search=COVID%20treatment&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
     Google Scholar
  24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229): 1033–1034.
    DOI  |   Google Scholar
  25. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021; 385(7): 585–594.
    DOI  |   Google Scholar
  26. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years - COVID-NET, 13 states, February-April 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(32): 1088–1093.
    DOI  |   Google Scholar
  27. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years - United States, January-march 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18): 674–679.
    DOI  |   Google Scholar
  28. van Gils MJ, Lavell AHA, van der Straten K, Appelman B, Bontjer I, Poniman M, et al. Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants [Internet]. bioRxiv. [Preprint]. 2021. http://dx.doi.org/10.1101/2021.09.27.21264163.
    DOI  |   Google Scholar
  29. Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant [Internet]. Khub.net. [Preprint] 2021. Available from: https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view/479607266.
     Google Scholar
  30. Jagadeesh Kumar V, Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M, et al. Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2 [Internet]. bioRxiv. [Preprint] 2021. http://dx.doi.org/10.1101/2021.07.13.21260417.
    DOI  |   Google Scholar
  31. Cevik M, Grubaugh ND, Iwasaki A, Openshaw P. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cell. 2021; 184(20): 5077–81.
    DOI  |   Google Scholar
  32. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10): 626–636.
    DOI  |   Google Scholar
  33. Chowdhury S, Bappy MH, Chowdhury S, Chowdhury MS, Chowdhury NS. COVID-19 induced cardiovascular complications and recent therapeutic advances. EJMED. 2021; 3(6): 17–22.
    DOI  |   Google Scholar
  34. Office of the Commissioner. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 Vaccine for certain populations [Internet]. Fda.gov. 2021 [cited 2021 Oct 24]. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations.
     Google Scholar
  35. Office of the Commissioner. Coronavirus (COVID-19) update: FDA takes additional actions on the use of a booster dose for COVID-19 vaccines [Internet]. Fda.gov. 2021 [cited 2021 Oct 24]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines.
     Google Scholar
  36. CDC. COVID-19 Vaccine Booster Shots [Internet]. Cdc.gov. 2021 [cited 2021 Oct 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html.
     Google Scholar


Most read articles by the same author(s)